Medicamen Biotech Limited (MEDICAMEQ) fundamentals
Medicamen Biotech Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as MEDICAMEQ (ISIN INE646B01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Medicamen Biotech Limited does
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider. The Company is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the global pharmaceutical industry. The Company’s focus areas include antibiotics, hypertension, general pain management, cardiovascular, diabetics and oncology formulations. In cardiology, the Company is delivering effective treatments for heart-related conditions. Its CNS products address neurological disorders, while its diabetology solutions focus on advanced diabetes management. It also contributes to the global fight against malaria with its anti-malarial medications. Additionally, the Company offers essential vitamins, antibiotics for bacterial infections, and comprehensive pain management solutions. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, and others.
Valuation and market data
| Last close | ₹302.00 |
|---|---|
| Market capitalisation | ₹354 crore |
| Enterprise value | ₹356 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.66 |
| Price to sales (TTM) | 1.72 |
| Book value per share | ₹181.88 |
| Dividend yield | 33.11% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Oct 27 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹182 crore | ₹12 crore | ₹9 crore | 0.00 |
| Mar 2025 | ₹158 crore | ₹13 crore | ₹9 crore | 7.43 |
| Mar 2024 | ₹175 crore | ₹17 crore | ₹13 crore | 10.50 |
| Mar 2023 | ₹140 crore | ₹17 crore | ₹15 crore | 12.04 |
| Mar 2022 | ₹117 crore | ₹18 crore | ₹15 crore | 12.20 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 40.5% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.4% |
| Retail and others | 59.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.